Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain

• Published in: International journal of environmental research and public health Vol. 17; no. 18; p. 6845
• Main Authors: Pérez-Belmonte, Luis M., López-Carmona, María D., Quevedo-Marín, Juan L., Ricci, Michele, Martín-Carmona, Jesica, Sanz-Cánovas, Jaime, López-Sampalo, Almudena, Martín-Escalante, María D., Bernal-López, M. Rosa, Gómez-Huelgas, Ricardo
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 19-09-2020; MDPI
• Subjects: Antibacterial agents; Antibiotics; Anticoagulants; Azithromycin; Bacterial infections; Clinical trials; Coronaviruses; Corticoids; Corticosteroids; COVID-19; Cytokines; Dexamethasone; Disease transmission; Drug dosages; Health services; Heparin; Hospitals; Hydroxychloroquine; Illnesses; Infections; Interleukin 1 receptor antagonist; Lopinavir; Methylprednisolone; Oxygen saturation; Pandemics; Patients; Pneumonia; Prednisone; Respiration; Respiratory diseases; Risk factors; Risk groups; Ritonavir; Severe acute respiratory syndrome coronavirus 2; Steroids; Thromboembolism; Thrombosis; Ventilation; Ventilators; Spain
• ISSN: 1660-4601; 1661-7827; 1660-4601
• DOI: 10.3390/ijerph17186845

Our objective was to compare clinical protocols for the treatment of the novel coronavirus disease 2019 (COVID-19) among different hospitals in Andalusia, Spain. We reviewed the current COVID-19 protocols of the 15 largest hospitals in Andalusia. Antiviral treatment, empirical antibacterial agents, adjunctive therapies, anticoagulant treatment, supportive care, hospital organization, and discharge recommendations were analyzed. All protocols included were the latest updates as of July 2020. Hydroxychloroquine in monotherapy was the most frequent antiviral drug recommended for mild respiratory illness with clinical risk factors (33.3%). Combined hydroxychloroquine with azithromycin or lopinavir/ritonavir was found in 40% of protocols. The recommended treatment for patients with mild and moderate pneumonias was different antiviral combinations including hydroxychloroquine plus azithromycin (93.3%) or hydroxychloroquine plus lopinavir/ritonavir (79.9%). Different combinations of hydroxychloroquine and lopinavir/ritonavir (46.7%) and triple therapy with hydroxychloroquine, azithromycin, and lopinavir/ritonavir (40%) were the most recommended treatments for patients with severe pneumonia. There were five corticosteroid regimens, which used dexamethasone, methylprednisolone, or prednisone, with different doses and treatment durations. Anakinra was included in seven protocols with six different regimens. All protocols included prophylactic heparin and therapeutic doses for thromboembolism. Higher prophylactic doses of heparin for high-risk patients and therapeutic doses for patients in critical condition were included in 53.3% and 33.3% of protocols, respectively. This study showed that COVID-19 protocols varied widely in several aspects (antiviral treatment, corticosteroids, anakinra, and anticoagulation for high risk of thrombosis or critical situation). Rigorous randomized clinical trials on the proposed treatments are needed to provide consistent evidence.